550+

Publications

4,000+

Impact factors

2,000+

Clinical Projects

HIGHLIGHTED STUDIES FOR CANCER EARLY DETECTION

  1. Multidimensional cell-free DNA fragmentomic assay for detection of early-stage lung cancer. American Journal of Respiratory and Critical Care Medicine. 2023 May 1;207(9):1203-1213. doi: 10.1164/rccm.202109-2019OC.
  2. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology. 2022 Aug;76(2):317-329. doi: 10.1002/hep.32308.
  3. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. 2022 Jul;81:104131. doi: 10.1016/j.ebiom.2022.104131.
  4. Letter to the Editor: an ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection. Molecular Cancer. 2022 Jun 11;21(1):129. doi: 10.1186/s12943-022-01594-w.
  5. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma. Journal of Hematology and Oncology. 2021 October 26;14,175. doi:10.1186/s13045-021-01189-w 

HIGHLIGHTED STUDIES FOR MINIMAL RESIDUAL DISEASE TRACKING

  1. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer. Journal of Hematology and Oncology. 2022 Oct 1;15(1):137. doi: 10.1186/s13045-022-01355-8.
  2. The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients. Molecular Cancer. 2022 May 19;21(1):117. doi: 10.1186/s12943-022-01590-0.
  3. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nature Communications. 2021 November 19; 12, 6770. doi:10.1038/s41467-021-27022-z
  4. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLoS Medicine. 2021 Aug 31;18(8):e1003741. doi: 10.1371/journal.pmed.1003741.
  5. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology. 2021 May 17;14(1):80. doi: 10.1186/s13045-021-01089-z.

OTHER HIGHLIGHTED STUDIES

  1. Enhanced detection of landmark minimal residual disease in lung cancer using cell-free DNA fragmentomics. Cancer Research Communications. 2023 May 16. doi.org/10.1158 /2767-9764.CRC-22-0363
  2. Tumor-naïve circulating tumor DNA as an early response biomarker for patients treated with immunotherapy in early phase clinical trials. JCO Precision Oncology. 2023 Apr;7:e2200509. doi: 10.1200/PO.22.00509.
  3. Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications. 2021 November 8; 12, 6454. doi:10.1038/s41467-021-26806-7
  4. Timing and origins of local and distant metastases in lung cancer. Journal of Thoracic Oncology. 2021 Mar 12. doi:10.1016/j.jtho.2021.02.023
  5. Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases: the Apollo study. Clinical Cancer Research. 2020 Dec 1;26(23):6168-6175. doi: 10.1158/1078-0432.CCR-20-2081.
  6. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters. 2020 Mar 1;472:108-118. doi: 10.1016/j.canlet.2019.12.004.
  7. Distribution of NRG1 gene fusions in a large population of Chinese patients with NSCLC. Journal of Thoracic Oncology. 2019 Dec;14(12):e263-e266. doi: 10.1016/j.jtho.2019.07.012.
  8. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small-cell lung cancer. Clinical Cancer Research. 2019 Aug 15;25(16):5015-5026. doi: 10.1158/1078-0432.CCR-19-0585.
  9. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019 Jul 28;9(19):5532-5541. doi: 10.7150/thno.34070.
  10. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019 Jul;68(7):1152-1161. doi: 10.1136/gutjnl-2018-316522.
  11. Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica. 2019 May;104(5):e195-e199. doi: 10.3324/haematol.2018.205369.
  12. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.
  13. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain. 2019 Jan 1;142(1):23-34. doi: 10.1093/brain/awy307
  14. Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. Clinical Cancer Research. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310.
  15. Circulating tumor DNA mutational profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Scientific Reports. 2017 Apr 3;7(1):583. doi: 10.1038/s41598-017-00520-1.
  16. The unique characteristics of MET Exon 14 mutation in Chinese patients with NSCLC. Journal of Thoracic Oncology. 2016 Sep;11(9):1503-10. doi: 10.1016/j.jtho.2016.05.016.
Read More